Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

Evernorth said in an announcement that through its Express Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says. Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 for participating patients. They also more deeply discount the drugs for employers and health plans that contract with ...

The benefit could nudge more Evernorth clients to cover GLP-1s. Currently, only half of its employer clients cover drugs like Wegovy and Zepbound for weight management, executives said on a call ...

The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from ...